Some of the questions that we've so far heard, and that we've posed ourselves, question how that's interpreted in the legislation. I think what we're looking to see is a clearer definition of which payer would come in and whether a private payer will be maintained. I think a number of the provinces that have spoken publicly on this issue have also raised the fact that they would be looking to add to their current public plans while maintaining the private aspect that they have in their jurisdictions.
It really would come down to some of the negotiations that would take place. In the legislation, we would recommend that there be clear reference to a mix of public and private payers to make sure that this mix is maintained in looking forward beyond diabetes and other potential medications that might be under consideration.